Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018224497) GONADOTROPIN-RELEASING HORMONE ANTAGONIST DOSING REGIMENS FOR TREATING UTERINE FIBROIDS AND REDUCING MENSTRUAL BLOOD LOSS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/224497 International Application No.: PCT/EP2018/064767
Publication Date: 13.12.2018 International Filing Date: 05.06.2018
IPC:
A61K 31/519 (2006.01) ,A61P 15/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519
ortho- or peri-condensed with heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
15
Drugs for genital or sexual disorders; Contraceptives
Applicants:
OBSEVA S.A. [CH/CH]; Chemin des Aulx 12 1228 Plan-les-Ouates, CH
Inventors:
LOUMAYE, Ernest; CH
GOTTELAND, Jean-Pierre; CH
POHL, Olivier; CH
Agent:
KATZAROV SA; Avenue des Morgines 12 1213 Petit-Lancy, CH
Priority Data:
62/515,23205.06.2017US
Title (EN) GONADOTROPIN-RELEASING HORMONE ANTAGONIST DOSING REGIMENS FOR TREATING UTERINE FIBROIDS AND REDUCING MENSTRUAL BLOOD LOSS
(FR) POSOLOGIES D'UN ANTAGONISTE DE L'HORMONE DE LIBÉRATION DES GONADOTROPHINES PERMETTANT DE TRAITER LES FIBROMES UTÉRINS ET DE RÉDUIRE LES PERTES DE SANG MENSTRUELLES
Abstract:
(EN) The invention provides compositions and methods for reducing the volume of menstrual blood loss in a patient, such as a human patient, for instance, that has uterine fibroids, by administration of a gonadotropin-releasing hormone (GnRH) antagonist. Suitable GnRH antagonists useful in conjunction with the compositions and methods described herein include thieno[3,4d]pyrimidine derivatives, such as 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxypheny I]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4d]pyrimidine-5-carboxylic acid and the choline salt thereof.
(FR) L'invention concerne des compositions et des procédés permettant de réduire le volume des pertes de sang menstruelles chez une patiente, telle qu'une patiente humaine, qui présente, par exemple des fibromes utérins, grâce à l'administration d'un antagoniste de l'hormone de libération des gonadotrophines (GnRH). Parmi les antagonistes de la GnRH appropriés utiles en association avec les compositions et les procédés décrits ici, on peut citer des dérivés de thiéno[3,4d]pyrimidine, tels que l'acide 3-[2-fluoro-5-(2,3-difluoro-6-méthoxybenzyloxy)-4-méthoxyphényI]-2,4-dioxo-1,2,3,4-tétrahydrothiéno[3,4d]pyrimidine-5-carboxylique et son sel de choline.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)